Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-5280 in newly diagnosed type 1 diabetes
NCT06057454Phase 1Completed
- Sponsor
- Rise Therapeutics
- Start
- Dec 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of R-5280 in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Rise Therapeutics. Primary endpoint: Adverse Events at 12 weeks. Started Dec 2023; status: completed.
02
Drugs
R-5280
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06057454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06057454.